Selected article for: "access barrier and acute respiratory"
Author: Zakynthinos, George E.; Tsolaki, Vasiliki; Bardaka, Foteini; Makris, Demosthenes
Title: Fixed dilated pupils in Covid-19 ARDS patients under rocuronium, reversed after discontinuation
  • Cord-id: 29wm8wli
  • Document date: 2021_7_13
    • ID: 29wm8wli
    Snippet: Neuromuscular Blockade Agents (NMBA) are used in the management of moderate and severe Acute Respiratory Distress Syndrome (ARDS) patients. They have never been reported to present Central Nervous System adverse reactions. Shortage of cis-atracurium during the pandemic, led to the use of rocuronium. We report three patients with Covid-19 ARDS, who presented bilateral dilated, non-reactive pupils, after continuous rocuronium infusion. Brain CT findings were unremarkable and transcranial doppler t
    Document: Neuromuscular Blockade Agents (NMBA) are used in the management of moderate and severe Acute Respiratory Distress Syndrome (ARDS) patients. They have never been reported to present Central Nervous System adverse reactions. Shortage of cis-atracurium during the pandemic, led to the use of rocuronium. We report three patients with Covid-19 ARDS, who presented bilateral dilated, non-reactive pupils, after continuous rocuronium infusion. Brain CT findings were unremarkable and transcranial doppler tracings did not suggest brain edema or hemorrhage. NMBA's discontinuation led to reversal of the pupillary dilation. We believe that impairment of Blood-Brain-Barrier, due to Covid-19, led rocuronium access into the Central Nervous System, leading to this adverse effect. Clinicians should be aware of this adverse reaction when managing patients with Covid-19 ARDS warranting NMBA use.

    Search related documents:
    Co phrase search for related documents
    • acquired pneumonia and acute respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acquired pneumonia and long period: 1
    • acquired pneumonia and lung protective ventilation: 1, 2
    • acquired pneumonia ards and acute respiratory: 1, 2, 3, 4, 5, 6, 7
    • acquired pneumonia ards and acute respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7
    • active metabolite and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
    • active metabolite and acute respiratory distress syndrome: 1, 2, 3
    • acute respiratory and adequate perfusion: 1
    • acute respiratory and adequate perfusion maintain: 1
    • acute respiratory and long period: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory and lung protective ventilation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory and lung protective ventilation facilitate: 1, 2, 3, 4, 5, 6
    • acute respiratory distress syndrome and adequate perfusion: 1
    • acute respiratory distress syndrome and adequate perfusion maintain: 1
    • acute respiratory distress syndrome and long period: 1, 2, 3, 4, 5, 6
    • acute respiratory distress syndrome and lung protective ventilation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress syndrome and lung protective ventilation facilitate: 1, 2, 3, 4, 5